CROSS COUNTRY HEALTHCARE INC (CCRN) Fundamental Analysis & Valuation
NASDAQ:CCRN • US2274831047
Current stock price
9.52 USD
+0.34 (+3.7%)
Last:
This CCRN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. CCRN Profitability Analysis
1.1 Basic Checks
- CCRN had positive earnings in the past year.
- In the past year CCRN had a positive cash flow from operations.
- The reported net income has been mixed in the past 5 years: CCRN reported negative net income in multiple years.
- CCRN had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
- The Return On Assets of CCRN (-21.13%) is worse than 80.00% of its industry peers.
- With a Return On Equity value of -29.38%, CCRN is not doing good in the industry: 68.00% of the companies in the same industry are doing better.
- CCRN has a worse Return On Invested Capital (0.54%) than 65.00% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for CCRN is below the industry average of 8.63%.
- The last Return On Invested Capital (0.54%) for CCRN is well below the 3 year average (6.06%), which needs to be investigated, but indicates that CCRN had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.13% | ||
| ROE | -29.38% | ||
| ROIC | 0.54% |
ROA(3y)-4.3%
ROA(5y)5%
ROE(3y)-5.84%
ROE(5y)13.62%
ROIC(3y)6.06%
ROIC(5y)14.51%
1.3 Margins
- CCRN has a Operating Margin of 0.24%. This is in the lower half of the industry: CCRN underperforms 65.00% of its industry peers.
- CCRN's Operating Margin has declined in the last couple of years.
- With a Gross Margin value of 20.26%, CCRN perfoms like the industry average, outperforming 46.00% of the companies in the same industry.
- CCRN's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.24% | ||
| PM (TTM) | N/A | ||
| GM | 20.26% |
OM growth 3Y-71.15%
OM growth 5Y-31.34%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.25%
GM growth 5Y-3.52%
2. CCRN Health Analysis
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CCRN is destroying value.
- Compared to 1 year ago, CCRN has less shares outstanding
- Compared to 5 years ago, CCRN has less shares outstanding
- CCRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 4.74 indicates that CCRN is not in any danger for bankruptcy at the moment.
- CCRN has a better Altman-Z score (4.74) than 82.00% of its industry peers.
- There is no outstanding debt for CCRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.74 |
ROIC/WACC0.06
WACC8.99%
2.3 Liquidity
- CCRN has a Current Ratio of 3.78. This indicates that CCRN is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of CCRN (3.78) is better than 88.00% of its industry peers.
- CCRN has a Quick Ratio of 3.78. This indicates that CCRN is financially healthy and has no problem in meeting its short term obligations.
- CCRN's Quick ratio of 3.78 is amongst the best of the industry. CCRN outperforms 89.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.78 | ||
| Quick Ratio | 3.78 |
3. CCRN Growth Analysis
3.1 Past
- The earnings per share for CCRN have decreased strongly by -95.56% in the last year.
- Measured over the past years, CCRN shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -46.59% on average per year.
- CCRN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -21.56%.
- CCRN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.74% yearly.
EPS 1Y (TTM)-95.56%
EPS 3Y-84.39%
EPS 5Y-46.59%
EPS Q2Q%-250%
Revenue 1Y (TTM)-21.56%
Revenue growth 3Y-27.85%
Revenue growth 5Y4.74%
Sales Q2Q%-23.61%
3.2 Future
- Based on estimates for the next years, CCRN will show a very strong growth in Earnings Per Share. The EPS will grow by 128.64% on average per year.
- CCRN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.18% yearly.
EPS Next Y388.12%
EPS Next 2Y128.64%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-8.87%
Revenue Next 2Y-2.17%
Revenue Next 3Y0.18%
Revenue Next 5YN/A
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. CCRN Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 476.00, which means the current valuation is very expensive for CCRN.
- Compared to the rest of the industry, the Price/Earnings ratio of CCRN indicates a slightly more expensive valuation: CCRN is more expensive than 60.00% of the companies listed in the same industry.
- When comparing the Price/Earnings ratio of CCRN to the average of the S&P500 Index (26.17), we can say CCRN is valued expensively.
- Based on the Price/Forward Earnings ratio of 97.52, the valuation of CCRN can be described as expensive.
- CCRN's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. CCRN is more expensive than 60.00% of the companies in the same industry.
- The average S&P500 Price/Forward Earnings ratio is at 23.05. CCRN is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 476 | ||
| Fwd PE | 97.52 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, CCRN is valued a bit cheaper than the industry average as 72.00% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, CCRN is valued cheaply inside the industry as 88.00% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.67 | ||
| EV/EBITDA | 9.72 |
4.3 Compensation for Growth
- The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- A more expensive valuation may be justified as CCRN's earnings are expected to grow with 128.64% in the coming years.
PEG (NY)1.23
PEG (5Y)N/A
EPS Next 2Y128.64%
EPS Next 3YN/A
5. CCRN Dividend Analysis
5.1 Amount
- CCRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CCRN Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:CCRN (4/6/2026, 3:23:11 PM)
9.52
+0.34 (+3.7%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-04 2026-03-04/amc
Earnings (Next)05-05 2026-05-05/amc
Inst Owners84.61%
Inst Owner Change0%
Ins Owners6.23%
Ins Owner Change17.24%
Market Cap307.69M
Revenue(TTM)1.05B
Net Income(TTM)-94.85M
Analysts74.67
Price Target11.9 (25%)
Short Float %4.46%
Short Ratio2.53
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-157.94%
Min EPS beat(2)-296.08%
Max EPS beat(2)-19.79%
EPS beat(4)1
Avg EPS beat(4)-107.17%
Min EPS beat(4)-296.08%
Max EPS beat(4)5.59%
EPS beat(8)3
Avg EPS beat(8)-61.22%
EPS beat(12)6
Avg EPS beat(12)-39.22%
EPS beat(16)10
Avg EPS beat(16)-25.76%
Revenue beat(2)0
Avg Revenue beat(2)-9.09%
Min Revenue beat(2)-9.46%
Max Revenue beat(2)-8.72%
Revenue beat(4)0
Avg Revenue beat(4)-7.87%
Min Revenue beat(4)-9.46%
Max Revenue beat(4)-5.84%
Revenue beat(8)0
Avg Revenue beat(8)-4.22%
Revenue beat(12)2
Avg Revenue beat(12)-2.78%
Revenue beat(16)5
Avg Revenue beat(16)-1.59%
PT rev (1m)2.55%
PT rev (3m)1.87%
EPS NQ rev (1m)-461.08%
EPS NQ rev (3m)-388.87%
EPS NY rev (1m)0%
EPS NY rev (3m)-19.12%
Revenue NQ rev (1m)-7.76%
Revenue NQ rev (3m)-7.76%
Revenue NY rev (1m)-3.67%
Revenue NY rev (3m)-3.67%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 476 | ||
| Fwd PE | 97.52 | ||
| P/S | 0.29 | ||
| P/FCF | 7.67 | ||
| P/OCF | 6.38 | ||
| P/B | 0.95 | ||
| P/tB | 1.33 | ||
| EV/EBITDA | 9.72 |
EPS(TTM)0.02
EY0.21%
EPS(NY)0.1
Fwd EY1.03%
FCF(TTM)1.24
FCFY13.03%
OCF(TTM)1.49
OCFY15.68%
SpS32.62
BVpS9.99
TBVpS7.16
PEG (NY)1.23
PEG (5Y)N/A
Graham Number2.12
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -21.13% | ||
| ROE | -29.38% | ||
| ROCE | 0.68% | ||
| ROIC | 0.54% | ||
| ROICexc | 0.76% | ||
| ROICexgc | 1.17% | ||
| OM | 0.24% | ||
| PM (TTM) | N/A | ||
| GM | 20.26% | ||
| FCFM | 3.8% |
ROA(3y)-4.3%
ROA(5y)5%
ROE(3y)-5.84%
ROE(5y)13.62%
ROIC(3y)6.06%
ROIC(5y)14.51%
ROICexc(3y)6.35%
ROICexc(5y)14.73%
ROICexgc(3y)10.08%
ROICexgc(5y)21.91%
ROCE(3y)7.68%
ROCE(5y)18.37%
ROICexgc growth 3Y-70.95%
ROICexgc growth 5Y-31.89%
ROICexc growth 3Y-71.51%
ROICexc growth 5Y-28.12%
OM growth 3Y-71.15%
OM growth 5Y-31.34%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.25%
GM growth 5Y-3.52%
F-Score6
Asset Turnover2.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 48.59% | ||
| Cap/Sales | 0.77% | ||
| Interest Coverage | 1.82 | ||
| Cash Conversion | 249.59% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.78 | ||
| Quick Ratio | 3.78 | ||
| Altman-Z | 4.74 |
F-Score6
WACC8.99%
ROIC/WACC0.06
Cap/Depr(3y)57.55%
Cap/Depr(5y)63.04%
Cap/Sales(3y)0.7%
Cap/Sales(5y)0.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-95.56%
EPS 3Y-84.39%
EPS 5Y-46.59%
EPS Q2Q%-250%
EPS Next Y388.12%
EPS Next 2Y128.64%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-21.56%
Revenue growth 3Y-27.85%
Revenue growth 5Y4.74%
Sales Q2Q%-23.61%
Revenue Next Year-8.87%
Revenue Next 2Y-2.17%
Revenue Next 3Y0.18%
Revenue Next 5YN/A
EBIT growth 1Y103.69%
EBIT growth 3Y-79.18%
EBIT growth 5Y-28.09%
EBIT Next Year297.63%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-64.01%
FCF growth 3Y-31.6%
FCF growth 5Y12.15%
OCF growth 1Y-59.83%
OCF growth 3Y-28.87%
OCF growth 5Y12.15%
CROSS COUNTRY HEALTHCARE INC / CCRN Fundamental Analysis FAQ
What is the ChartMill fundamental rating of CROSS COUNTRY HEALTHCARE INC (CCRN) stock?
ChartMill assigns a fundamental rating of 4 / 10 to CCRN.
What is the valuation status for CCRN stock?
ChartMill assigns a valuation rating of 4 / 10 to CROSS COUNTRY HEALTHCARE INC (CCRN). This can be considered as Fairly Valued.
What is the profitability of CCRN stock?
CROSS COUNTRY HEALTHCARE INC (CCRN) has a profitability rating of 2 / 10.
What is the valuation of CROSS COUNTRY HEALTHCARE INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CROSS COUNTRY HEALTHCARE INC (CCRN) is 476 and the Price/Book (PB) ratio is 0.95.
Can you provide the financial health for CCRN stock?
The financial health rating of CROSS COUNTRY HEALTHCARE INC (CCRN) is 9 / 10.